Advance Search

ANALISIS EFEKTIVITAS TERAPI PADA PASIEN ANEMIA GAGAL GINJAL HEMODIALISIS DI RSUP DR. WAHIDIN SUDIROHUSODO MAKASSAR

DOI: https://doi.org/10.20956/mff.v22i1.5690
Article History

Submited : December 19, 2018
Published : December 19, 2018

Penelitian ini bertujuan untuk menganalisis efektivitas terapi anemia penggunaan EPO,PRC pada pasien gagal ginjal hemodialisis berdasarkan outcome terhadap parameter hematologi meliputi kadar RBC,Hgb,Hct,MCV,MCH,MCHC pasien selama rawat inap di RSUP Dr. Wahidin Sudirohusodo Makassar.Desain penelitian yang digunakan adalah penelitian prospektif dengan rancangan deskriptif. Pengambilan sampel dilakukan dengan teknik non-probability sampling dengan cara purposive sampling, yang mencapai jumlah 27 orang sampel. Data yang dianalisis secara deskriptif berupa parameter hematologi. Hasil penelitian menunjukkan terapi EPO efektif meningkatkan kadar RBC,Hgb,Hct dan MCV pada pasien anemia hemodialisis. Terapi PRC efektif meningkatkan kadar RBC,Hgb,Hct pada pasien anemia hemodialisis. Interaksi obat potensial bermakna yang terjadi antara EPO dengan obat lain yaitu antihipertensi golongan angiotensin receptor blocker.

References

  1. Riskesdas. Riset Kesehatan Dasar 2013. Jakarta: Kementerian Kesehatan.
  2. Perhimpunan Nefrologi Indonesia (PERNEFRI). Konsensus manajemen anemia pada penyakit ginjal kronik, 2011. Jakarta; 2011.hlm. 3-15.
  3. Srinivasan, R., Fredy, C., Saravanan, J., Mohanta, P. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients. Biomedicine & Pharmacotherapy 82 (2016) 44–48.
  4. Dipiro, J., Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, dan L. Michael Posey. Pharmacotherapy a Pathophysiologic Approach. Seventh Edition. The McGraw-Hill Companies, USA,2008.
  5. Koda – Kimble and young’s. Applied Theraupetic the clinical Use of Drugs tenth edition, Lippincott Williams & Wilkins, awolterskluwer business two commerce square,2009.
  6. C. Macdougall, Daniel W. Coyne, David Goldsmith. New options for the anemia of chronic kidney disease.2017.
  7. KDIGO.Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.Kidney Int,2013; 2: 1.
  8. C. Macdougall. 2015. Anemia and Chronic Renal Failure, UK.
  9. KDIGO. Red cell transfusion to treat anemia in CKD. Kidney International Supplements; 2012. hlm. 311–6
  10. Suwitra, K., 2009. Penyakit Ginjal Kronik, dalam: Buku Ajar Ilmu Penyakit Dalam. hal. 1035–40.
  11. Wish, J. ANEMIA IN CHRONIC KIDNEY DISEASE.2012
  12. Almeida, F.A.A., Machado, F.C., Moura, J.A., dan Guimarães, A. C. Global AndCardiovascular Mortality and Risk Factors in Patients Under Hemodialysis Treatment. ArquivosBrasileiros De Cardiologia, 2010; 94: 187–192, 201–206, 190–195.
  13. Mohanram A, Zhang Z, Shahinfar S. 2008. The Effect of Losartan on Hemoglobin Concentration and Renal Outcome in Diabetic Nephropathy of Type 2 Diabetes. Kidney. 73(5):630–6.
  14. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. Edisi ke-12. Philadelphia: Elsevier-Saunders, 2014: 389-91, 1029-44.
  15. Wilson LM. Penyakit ginjal kronik. In: Hartanto H, Susi N, Wulansari P, Mahanani DA, editors: Patofisiologi konsep klinis proses-proses penyakit. 6nd ed. Jakarta: EGC; 2012.p. 912-45.
  16. Singh AK. Anemia of Chronic Kidney Disease. Clin J Am 2008; vol. 3: 3-6.
  17. Bakris, George, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases. 2008;5: S46-S55.
  18. Baxter, Karen. 2008. Stockley’s Drug Interactions. Eighth Edition. Pharmaceutical Press, UK.
Insani, N., Manggau, M. A., & Kasim, H. (2018). ANALISIS EFEKTIVITAS TERAPI PADA PASIEN ANEMIA GAGAL GINJAL HEMODIALISIS DI RSUP DR. WAHIDIN SUDIROHUSODO MAKASSAR. Majalah Farmasi Dan Farmakologi, 22(1), 13-15. https://doi.org/10.20956/mff.v22i1.5690

Downloads

Download data is not yet available.
Fulltext
PDF